Detalles de la búsqueda
1.
Development of Human Target Validation Classification that Predicts Future Clinical Efficacy.
J Pharmacol Exp Ther
; 368(2): 255-261, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30482795
2.
Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defects.
Cardiovasc Diabetol
; 15: 36, 2016 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-26892461
3.
Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
Br J Clin Pharmacol
; 80(6): 1362-73, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26174611
4.
Histone deacetylase inhibitors stimulate tissue-type plasminogen activator production in vascular endothelial cells.
J Thromb Thrombolysis
; 35(2): 185-92, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23229086
5.
Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837.
Eur J Clin Pharmacol
; 66(9): 903-10, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20535457
6.
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Eur Heart J
; 30(23): 2897-907, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19690349
7.
Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study.
Clin Drug Investig
; 30(7): 461-71, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20528001
8.
Effects of IL-1beta and IL-6 on tissue-type plasminogen activator expression in vascular endothelial cells.
Thromb Res
; 123(2): 342-51, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18502475
9.
Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
N Engl J Med
; 349(18): 1713-21, 2003 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-14585939
10.
Trousseau's syndrome - what is the evidence? A population-based autopsy study.
Thromb Haemost
; 95(3): 541-5, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16525584
11.
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Thromb Haemost
; 95(3): 447-53, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16525572
12.
Developing New Treatments for Heart Failure: Focus on the Heart.
Circ Heart Fail
; 9(5)2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27166246
13.
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
Clin Pharmacol Ther
; 77(4): 279-90, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15903126
14.
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
Thromb Haemost
; 94(3): 522-7, 2005 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16268466
15.
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Thromb Haemost
; 91(6): 1090-6, 2004 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15175794
16.
No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Clin Pharmacokinet
; 42(8): 755-64, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12846596
17.
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Thromb Res
; 107(3-4): 93-9, 2002 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12431473
18.
Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
Blood Coagul Fibrinolysis
; 14(7): 677-84, 2003 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-14517494
19.
Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
Thromb Res
; 129(4): e83-91, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21925716
20.
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Thromb Res
; 127(2): 91-9, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21172721